Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Clinical Trials

30 clinical trials for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) — RECRUITING · PHASE2
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — RECRUITING · PHASE1
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery — RECRUITING · PHASE2
• A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer — COMPLETED · PHASE2
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor — COMPLETED · PHASE1
• Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer — OTHER · PHASE2
• Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study — COMPLETED
• Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. — NOT_YET_RECRUITING
• A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older — TERMINATED · NA
• PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) — COMPLETED · PHASE2
• Patterns of Prescribing and Monitoring of Palbociclib — COMPLETED
• Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer — COMPLETED
• Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant — COMPLETED · PHASE2
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients — TERMINATED · PHASE3
• Palbociclib With Everolimus + Exemestane In BC — COMPLETED · PHASE1
• Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer — TERMINATED · PHASE1
• 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer — COMPLETED · PHASE3
• ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism — COMPLETED · PHASE1
• Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer — OTHER · PHASE2
• Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer — TERMINATED · PHASE2
• GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer — TERMINATED · PHASE1
• Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients — OTHER · PHASE2
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer — OTHER · PHASE3
• Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer — COMPLETED · PHASE1
• Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients — COMPLETED · PHASE2
• Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients — OTHER

Refine this search